1609678-68-3

Basic information

• Product Name: N-{4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-3-ethynylbenzamide
• Synonyms: N-{4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-3-ethynylbenzamide
• CAS NO: 1609678-68-3
• Molecular Weight: 415.458
• Mol File: 1609678-68-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N-{4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-3-ethynylbenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-{4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-3-ethynylbenzamide(1609678-68-3)
• EPA Substance Registry System: N-{4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-3-ethynylbenzamide(1609678-68-3)

Safety Data

• Hazardous Substances Data: 1609678-68-3(Hazardous Substances Data)

Upstream product

• 10601-99-7 3-ethynylbenzoic acid 
• 77123-59-2 methyl 3-<(trimethylsilyl)ethynyl>benzoate 
• 618-91-7 methyl 3-iodo-benzoate 
• 618-51-9 3-Iodobenzoic acid 
• 630125-91-6 4-(4-ethylpiperazin-1-ylmethyl)-3-trifluoromethylphenylamine 
• 143587-37-5 3-ethynylbenzoyl chloride 

Relevant articles and documents

NOVEL INDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING CANCER CONTAINING THE SAME

Disclosed are a compound selected from novel indazole derivatives, pharmaceutically acceptable salts thereof, hydrates thereof and stereoisomers thereof, a method for preparing the compound, and a pharmaceutical composition for preventing, alleviating or treating cancer containing the compound as an active ingredient. The novel indazole derivatives exhibit excellent ABL/DDR1 inhibitory efficacy and anti-proliferative efficacy against cancer cells, specifically blood cancer cells, and inhibitory activity against ABL T315I point mutations, thus being useful for the prevention, alleviation or treatment of cancer, specifically blood cancer, especially chronic myelogenous leukemia.

SUBSTITUTED PYRIMIDINYL AND PYRIDINYL-PYRROLOPYRIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS

The present invention relates to substituted pyrimidinyl- and pyridinylpyrrolopyridinone compounds which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular RET family kinases. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions containing these compounds.